NR 511 CEA EXAM 2026–2027 | (100
QUESTIONS AND CORRECT ANSWERS) |
ALREADY GRADED A+ | 100% VERIFIED
Chamberlain University | Advanced Practice Nursing | Key Domains: Differential Diagnosis,
Advanced Clinical Reasoning, Diagnostic Testing, Evidence-Based Practice, Patient Safety,
Health Promotion, Disease Management, and Comprehensive Clinical Assessment | Expert-
Aligned Structure | Exam-Ready Format
Introduction
This structured NR 511 CEA Exam format for 2026–2027 provides the complete layout for
generating high-quality exam-style questions with correct answers and rationales. It
emphasizes differential diagnosis, advanced clinical reasoning, evidence-based practice,
and patient safety principles critical to advanced nursing practice and successful
comprehensive exit assessment preparation.
Answer Format
All correct answers must appear in bold and cyan, accompanied by concise rationales
explaining safety/clinical reasoning, code adherence, and why alternative options are less
appropriate.
,Question 1: A 52-year-old male with a history of essential hypertension and type 2 diabetes
presents for a routine follow-up. His blood pressure today is 154/92 mmHg, confirmed on
repeat measurement. His current medication regimen includes metformin 1000 mg twice daily
and amlodipine 5 mg daily. According to current ACC/AHA and ADA guidelines, which of the
following is the most appropriate next step in managing his hypertension?
A. Increase amlodipine to 10 mg daily and schedule a follow-up in 3 months
B. Add lisinopril 10 mg daily and monitor renal function and serum potassium in 1 to 2 weeks
C. Add metoprolol succinate 50 mg daily to reduce cardiac workload
D. Switch amlodipine to hydrochlorothiazide 25 mg daily
Correct Answer: B. Add lisinopril 10 mg daily and monitor renal function and serum
potassium in 1 to 2 weeks
Rationale: In patients with diabetes and hypertension, ACE inhibitors (like lisinopril) or
ARBs are first-line agents due to their proven renal protective effects and reduction in
microvascular/macrovascular events, especially when blood pressure is above the target of
<130/80 mmHg. Increasing amlodipine (option A) is possible but does not provide the
specific renoprotective benefits of an ACEI in a diabetic patient. Beta-blockers (option C) are
not first-line for primary hypertension without compelling indications (e.g., heart failure,
post-MI). Switching to hydrochlorothiazide (option D) removes an effective calcium channel
blocker rather than adding a needed ACEI/ARB.
Question 2: During a routine physical examination of a 68-year-old female with no prior
history of heart disease, you auscultate a harsh, crescendo-decrescendo systolic ejection
murmur at the right second intercostal space that radiates to the carotid arteries. The patient
reports mild exertional dyspnea over the past three months. What is the most likely diagnosis
and appropriate initial diagnostic evaluation?
A. Mitral regurgitation; obtain a transesophageal echocardiogram (TEE)
B. Aortic stenosis; order a transthoracic echocardiogram (TTE)
C. Mitral valve prolapse; schedule an outpatient Holter monitor
D. Aortic regurgitation; perform an immediate exercise stress test
Correct Answer: B. Aortic stenosis; order a transthoracic echocardiogram (TTE)
Rationale: A harsh, crescendo-decrescendo systolic ejection murmur heard best at the right
upper sternal border (second intercostal space) with radiation to the carotids is the classic
presentation of aortic stenosis. Transthoracic echocardiography (TTE) is the diagnostic
standard to quantify valve hemodynamics and assess left ventricular function. Mitral
regurgitation (option A) causes a holosystolic murmur at the apex radiating to the axilla.
Mitral valve prolapse (option C) produces a mid-systolic click and late systolic murmur.
Aortic regurgitation (option D) produces a diastolic decrescendo murmur; furthermore,
exercise stress testing is contraindicated in symptomatic severe aortic stenosis.
,Question 3: A 45-year-old African American male presents for evaluation of newly diagnosed
essential hypertension. His blood pressure across three separate visits averages 146/92
mmHg. He has no past medical history of diabetes or chronic kidney disease (CKD). Based on
the ACC/AHA hypertension guidelines, which medication class is recommended as first-line
monotherapy for this patient?
A. Angiotensin-converting enzyme inhibitor (ACEI) such as enalapril
B. Beta-blocker such as atenolol
C. Thiazide-type diuretic or calcium channel blocker (CCB) such as chlorthalidone or
amlodipine
D. Loop diuretic such as furosemide
Correct Answer: C. Thiazide-type diuretic or calcium channel blocker (CCB) such as
chlorthalidone or amlodipine
Rationale: According to the ACC/AHA high blood pressure guidelines, in Black adults with
hypertension but without heart failure or chronic kidney disease (CKD), initial
antihypertensive treatment should include a thiazide-type diuretic or a calcium channel
blocker (CCB). ACE inhibitors (option A) and ARBs are less effective as monotherapy in this
demographic unless CKD is present. Beta-blockers (option B) are not first-line therapy in the
absence of specific cardiovascular indications. Loop diuretics (option D) are reserved for fluid
overload states like heart failure or advanced CKD.
Question 4: A 62-year-old male with a known history of peripheral arterial disease (PAD) and
intermittent claudication asks about pharmacological therapy to improve his walking distance.
He is currently taking aspirin 81 mg daily and atorvastatin 40 mg daily. He has no history of
heart failure. Which medication has the best evidence for improving walking distance in
patients with claudication?
A. Cilostazol 100 mg twice daily
B. Clopidogrel 75 mg daily
C. Pentoxifylline 400 mg three times daily
D. Warfarin adjusted to an INR of 2.0 to 3.0
Correct Answer: A. Cilostazol 100 mg twice daily
Rationale: Cilostazol, a phosphodiesterase III inhibitor with direct vasodilatory and
antiplatelet properties, is an FDA-approved first-line pharmacological agent proven to
significantly increase walking distance in patients with intermittent claudication. It is
contraindicated in patients with any degree of heart failure. Clopidogrel (option B) is an
excellent antiplatelet for cardiovascular risk reduction but does not actively improve
claudication distance. Pentoxifylline (option C) has been shown in trials to be largely
ineffective. Warfarin (option D) is not indicated for chronic PAD and increases major bleeding
risk.
, Question 5: A 55-year-old female presents to the clinic complaining of sudden onset
palpitations, fatigue, and mild shortness of breath that started two days ago. An in-office 12-
lead ECG reveals an irregularly irregular rhythm with absence of distinct P waves and a
ventricular rate of 124 bpm. What is the most appropriate initial management priority for this
patient?
A. Administer sublingual nitroglycerin 0.4 mg immediately
B. Schedule an urgent outpatient direct current (DC) cardioversion within 24 hours
C. Initiate rate control therapy with a beta-blocker or non-dihydropyridine CCB and assess
thromboembolic risk using the CHA2DS2-VASc score
D. Start amiodarone 200 mg daily for immediate rhythm control
Correct Answer: C. Initiate rate control therapy with a beta-blocker or non-
dihydropyridine CCB and assess thromboembolic risk using the CHA2DS2-VASc score
Rationale: The ECG description of an irregularly irregular rhythm without P waves confirms
atrial fibrillation (AFib). In stable new-onset AFib with a rapid ventricular response, the
primary initial management goals are rate control (using beta-blockers like metoprolol or
non-dihydropyridine CCBs like diltiazem) and anticoagulation assessment using the
CHA2DS2-VASc score. Nitroglycerin (option A) is for anginal ischemia. Urgent cardioversion
(option B) without prior anticoagulation or a TEE in AFib lasting >48 hours (or unknown
duration) risks dislodging a left atrial appendage thrombus, causing a stroke. Primary rhythm
control with amiodarone (option D) is not first-line for general stable AFib management.
Question 6: A 64-year-old male with HFrEF (Heart Failure with Reduced Ejection Fraction,
LVEF 32%) is stable on sacubitril/valsartan, bisoprolol, and dapagliflozin. He continues to
experience NYHA Class II symptoms. His serum potassium is 4.3 mEq/L and eGFR is 54
mL/min/1.73m2. Which medication should be added to his regimen to further reduce
mortality and hospitalization?
A. Furosemide 40 mg daily
B. Spironolactone 25 mg daily
C. Digoxin 0.125 mg daily
D. Verapamil 120 mg daily
Correct Answer: B. Spironolactone 25 mg daily
Rationale: In patients with symptomatic HFrEF (NYHA Class II-IV) who have an eGFR >30
mL/min and serum potassium <5.0 mEq/L, adding a mineralocorticoid receptor antagonist
(MRA) like spironolactone or eplerenone is strongly recommended by ACC/AHA guidelines to
further reduce cardiovascular mortality and heart failure hospitalizations (completing
guideline-directed medical therapy). Furosemide (option A) is used for symptom relief of
volume overload but does not independently reduce mortality. Digoxin (option C) reduces
hospitalizations but has no mortality benefit. Verapamil (option D), a negative inotrope, is
strictly contraindicated in HFrEF.
QUESTIONS AND CORRECT ANSWERS) |
ALREADY GRADED A+ | 100% VERIFIED
Chamberlain University | Advanced Practice Nursing | Key Domains: Differential Diagnosis,
Advanced Clinical Reasoning, Diagnostic Testing, Evidence-Based Practice, Patient Safety,
Health Promotion, Disease Management, and Comprehensive Clinical Assessment | Expert-
Aligned Structure | Exam-Ready Format
Introduction
This structured NR 511 CEA Exam format for 2026–2027 provides the complete layout for
generating high-quality exam-style questions with correct answers and rationales. It
emphasizes differential diagnosis, advanced clinical reasoning, evidence-based practice,
and patient safety principles critical to advanced nursing practice and successful
comprehensive exit assessment preparation.
Answer Format
All correct answers must appear in bold and cyan, accompanied by concise rationales
explaining safety/clinical reasoning, code adherence, and why alternative options are less
appropriate.
,Question 1: A 52-year-old male with a history of essential hypertension and type 2 diabetes
presents for a routine follow-up. His blood pressure today is 154/92 mmHg, confirmed on
repeat measurement. His current medication regimen includes metformin 1000 mg twice daily
and amlodipine 5 mg daily. According to current ACC/AHA and ADA guidelines, which of the
following is the most appropriate next step in managing his hypertension?
A. Increase amlodipine to 10 mg daily and schedule a follow-up in 3 months
B. Add lisinopril 10 mg daily and monitor renal function and serum potassium in 1 to 2 weeks
C. Add metoprolol succinate 50 mg daily to reduce cardiac workload
D. Switch amlodipine to hydrochlorothiazide 25 mg daily
Correct Answer: B. Add lisinopril 10 mg daily and monitor renal function and serum
potassium in 1 to 2 weeks
Rationale: In patients with diabetes and hypertension, ACE inhibitors (like lisinopril) or
ARBs are first-line agents due to their proven renal protective effects and reduction in
microvascular/macrovascular events, especially when blood pressure is above the target of
<130/80 mmHg. Increasing amlodipine (option A) is possible but does not provide the
specific renoprotective benefits of an ACEI in a diabetic patient. Beta-blockers (option C) are
not first-line for primary hypertension without compelling indications (e.g., heart failure,
post-MI). Switching to hydrochlorothiazide (option D) removes an effective calcium channel
blocker rather than adding a needed ACEI/ARB.
Question 2: During a routine physical examination of a 68-year-old female with no prior
history of heart disease, you auscultate a harsh, crescendo-decrescendo systolic ejection
murmur at the right second intercostal space that radiates to the carotid arteries. The patient
reports mild exertional dyspnea over the past three months. What is the most likely diagnosis
and appropriate initial diagnostic evaluation?
A. Mitral regurgitation; obtain a transesophageal echocardiogram (TEE)
B. Aortic stenosis; order a transthoracic echocardiogram (TTE)
C. Mitral valve prolapse; schedule an outpatient Holter monitor
D. Aortic regurgitation; perform an immediate exercise stress test
Correct Answer: B. Aortic stenosis; order a transthoracic echocardiogram (TTE)
Rationale: A harsh, crescendo-decrescendo systolic ejection murmur heard best at the right
upper sternal border (second intercostal space) with radiation to the carotids is the classic
presentation of aortic stenosis. Transthoracic echocardiography (TTE) is the diagnostic
standard to quantify valve hemodynamics and assess left ventricular function. Mitral
regurgitation (option A) causes a holosystolic murmur at the apex radiating to the axilla.
Mitral valve prolapse (option C) produces a mid-systolic click and late systolic murmur.
Aortic regurgitation (option D) produces a diastolic decrescendo murmur; furthermore,
exercise stress testing is contraindicated in symptomatic severe aortic stenosis.
,Question 3: A 45-year-old African American male presents for evaluation of newly diagnosed
essential hypertension. His blood pressure across three separate visits averages 146/92
mmHg. He has no past medical history of diabetes or chronic kidney disease (CKD). Based on
the ACC/AHA hypertension guidelines, which medication class is recommended as first-line
monotherapy for this patient?
A. Angiotensin-converting enzyme inhibitor (ACEI) such as enalapril
B. Beta-blocker such as atenolol
C. Thiazide-type diuretic or calcium channel blocker (CCB) such as chlorthalidone or
amlodipine
D. Loop diuretic such as furosemide
Correct Answer: C. Thiazide-type diuretic or calcium channel blocker (CCB) such as
chlorthalidone or amlodipine
Rationale: According to the ACC/AHA high blood pressure guidelines, in Black adults with
hypertension but without heart failure or chronic kidney disease (CKD), initial
antihypertensive treatment should include a thiazide-type diuretic or a calcium channel
blocker (CCB). ACE inhibitors (option A) and ARBs are less effective as monotherapy in this
demographic unless CKD is present. Beta-blockers (option B) are not first-line therapy in the
absence of specific cardiovascular indications. Loop diuretics (option D) are reserved for fluid
overload states like heart failure or advanced CKD.
Question 4: A 62-year-old male with a known history of peripheral arterial disease (PAD) and
intermittent claudication asks about pharmacological therapy to improve his walking distance.
He is currently taking aspirin 81 mg daily and atorvastatin 40 mg daily. He has no history of
heart failure. Which medication has the best evidence for improving walking distance in
patients with claudication?
A. Cilostazol 100 mg twice daily
B. Clopidogrel 75 mg daily
C. Pentoxifylline 400 mg three times daily
D. Warfarin adjusted to an INR of 2.0 to 3.0
Correct Answer: A. Cilostazol 100 mg twice daily
Rationale: Cilostazol, a phosphodiesterase III inhibitor with direct vasodilatory and
antiplatelet properties, is an FDA-approved first-line pharmacological agent proven to
significantly increase walking distance in patients with intermittent claudication. It is
contraindicated in patients with any degree of heart failure. Clopidogrel (option B) is an
excellent antiplatelet for cardiovascular risk reduction but does not actively improve
claudication distance. Pentoxifylline (option C) has been shown in trials to be largely
ineffective. Warfarin (option D) is not indicated for chronic PAD and increases major bleeding
risk.
, Question 5: A 55-year-old female presents to the clinic complaining of sudden onset
palpitations, fatigue, and mild shortness of breath that started two days ago. An in-office 12-
lead ECG reveals an irregularly irregular rhythm with absence of distinct P waves and a
ventricular rate of 124 bpm. What is the most appropriate initial management priority for this
patient?
A. Administer sublingual nitroglycerin 0.4 mg immediately
B. Schedule an urgent outpatient direct current (DC) cardioversion within 24 hours
C. Initiate rate control therapy with a beta-blocker or non-dihydropyridine CCB and assess
thromboembolic risk using the CHA2DS2-VASc score
D. Start amiodarone 200 mg daily for immediate rhythm control
Correct Answer: C. Initiate rate control therapy with a beta-blocker or non-
dihydropyridine CCB and assess thromboembolic risk using the CHA2DS2-VASc score
Rationale: The ECG description of an irregularly irregular rhythm without P waves confirms
atrial fibrillation (AFib). In stable new-onset AFib with a rapid ventricular response, the
primary initial management goals are rate control (using beta-blockers like metoprolol or
non-dihydropyridine CCBs like diltiazem) and anticoagulation assessment using the
CHA2DS2-VASc score. Nitroglycerin (option A) is for anginal ischemia. Urgent cardioversion
(option B) without prior anticoagulation or a TEE in AFib lasting >48 hours (or unknown
duration) risks dislodging a left atrial appendage thrombus, causing a stroke. Primary rhythm
control with amiodarone (option D) is not first-line for general stable AFib management.
Question 6: A 64-year-old male with HFrEF (Heart Failure with Reduced Ejection Fraction,
LVEF 32%) is stable on sacubitril/valsartan, bisoprolol, and dapagliflozin. He continues to
experience NYHA Class II symptoms. His serum potassium is 4.3 mEq/L and eGFR is 54
mL/min/1.73m2. Which medication should be added to his regimen to further reduce
mortality and hospitalization?
A. Furosemide 40 mg daily
B. Spironolactone 25 mg daily
C. Digoxin 0.125 mg daily
D. Verapamil 120 mg daily
Correct Answer: B. Spironolactone 25 mg daily
Rationale: In patients with symptomatic HFrEF (NYHA Class II-IV) who have an eGFR >30
mL/min and serum potassium <5.0 mEq/L, adding a mineralocorticoid receptor antagonist
(MRA) like spironolactone or eplerenone is strongly recommended by ACC/AHA guidelines to
further reduce cardiovascular mortality and heart failure hospitalizations (completing
guideline-directed medical therapy). Furosemide (option A) is used for symptom relief of
volume overload but does not independently reduce mortality. Digoxin (option C) reduces
hospitalizations but has no mortality benefit. Verapamil (option D), a negative inotrope, is
strictly contraindicated in HFrEF.
